Bjork Elisabeth sold $2.0M of PHVS

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

Pharvaris (PHVS) reported that its deucrictibant tablets reduced HAE attack rates by 83% in a Phase 3 trial. The study met primary and secondary endpoints. PHVS plans a 2027 FDA submission. Results showed sustained attack-rate reductions and no serious adverse events.

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

Pharvaris (PHVS) reported an 83% reduction in HAE attacks with deucrictibant XR in a Phase III trial, meeting all endpoints. The company plans to submit an NDA for prophylaxis in H1 2027, following a July 2026 filing for the IR formulation. Deucrictibant targets the bradykinin B2 receptor, offering a new oral mechanism in the competitive HAE market.

Pharvaris plans to seek US approval for deucrictibant XR after Phase III trial success in treating hereditary angioedema (HAE). The drug showed an 83% reduction in HAE attacks vs. placebo. The company aims to file an NDA in early 2027, facing competition from Takeda's Takhzyro and BioCryst's Orladeyo.

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.